Related Experiment Video
Updated: May 30, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
[Biomarkers of response to molecular targeted therapy in renal cell carcinoma]
Ryuichi Mizuno1, Mototsugu Oya
1Dept. of Urology, Keio University School of Medicine, Tokyo, Japan.
Abstract:
Therapeutic options for metastatic renal cell carcinoma (mRCC) have been evolving rapidly, with the approval of a variety of effective molecular targeted agents. With increasing choices of treatment modalities that may potentially improve survival, it is of great clinical benefit to be able to predict the clinical outcome of mRCC patients treated with molecular targeted agents. In addition, predictors of severe adverse events are warranted since those molecular targeted agents present a toxicity profile that is very different from that of conventional chemotherapeutic agents. Their use requires knowledge of a large number of possible adverse events. Although validation of previous criteria, such as the Motzer criteria, is important, a further implementation of RCC molecular biology knowledge would be ideal for finding a new predictive marker in this new age of molecular targeted therapies. The most prominent biomarker is vascular endothelial-derived growth factor (VEGF). Those patients who presented low serum VEGF showed prolonged progression-free survival when treated with sunitinib. Genetic markers such as single nucleotide polymorphisms (SNPs) are continuously being validated as markers, predicting molecular targeted therapy response as well as severe adverse events. The identification of biomarkers that predict response or severe adverse events from molecular targeted agents will aid in patient selection and guide therapy development.
Insights
Predicting treatment outcomes for metastatic renal cell carcinoma (mRCC) is crucial. Biomarkers like vascular endothelial-derived growth factor (VEGF) and genetic markers (SNPs) show promise in guiding molecular targeted therapies and predicting patient response and adverse events.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Context:
- Metastatic renal cell carcinoma (mRCC) treatment landscape is rapidly evolving with new molecular targeted agents.
- Predicting patient outcomes and severe adverse events is critical for effective clinical management.
- Existing predictive criteria require further enhancement with molecular insights.
Purpose:
- To explore the role of biomarkers in predicting clinical outcomes for mRCC patients treated with molecular targeted agents.
- To identify potential predictors of severe adverse events associated with these novel therapies.
- To highlight the importance of integrating molecular biology knowledge into predictive marker development for mRCC.
Summary:
- Vascular endothelial-derived growth factor (VEGF) is a prominent biomarker; low serum VEGF levels correlate with prolonged progression-free survival in patients treated with sunitinib.
- Genetic markers, specifically single nucleotide polymorphisms (SNPs), are being validated for their ability to predict response and severe adverse events to molecular targeted therapies.
- The study emphasizes the need for identifying robust biomarkers to personalize mRCC treatment strategies.
Impact:
- Facilitates patient selection for targeted therapies, optimizing treatment efficacy.
- Aids in the development of novel therapeutic strategies by guiding drug discovery and clinical trial design.
- Improves patient management by enabling prediction of treatment response and potential toxicities, thereby enhancing survival and quality of life.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...